Inflammation

Latest News

Red FDA approval stamp | image credit: chrisdorney - stock.adobe.com

FDA Approves Dupilumab to Treat EoE for Children Under 12 Years

January 25th 2024

The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.

Vitamin D Concept | image credit: ExQuisine - stock.adobe.com

Vitamin D Supplementation Does Not Significantly Help Psoriasis

By Chelsie Derman

December 28th 2023

Obesity Concept | image credit: high_resolution - stock.adobe.com

Psoriasis Associated with Being Overweight, Obesity, Study Finds

By Chelsie Derman

December 28th 2023

Woman Enduring Arthritic Pain in Hand | image credit: keiferpix - stock.adobe.com

Weight Loss or Gain Not Linked to Outcomes in Hand Osteoarthritis

By Kyle Munz

December 23rd 2023

Top 5 Most-Read Inflammation Content of 2023

By Kyle Munz

December 18th 2023

Recommended Guidelines and Restrictions in Asthma

Defining the recommended guidelines and the formulary restrictions with the standard of care for asthma.

Visit Now

Use of Biologics for the Treatment of Asthma panelists

Continuing Medical Education

View All

November 21st 2024

Emerging Concepts and Approaches in the Treatment of Food Allergy: What Managed Care Professionals Need to Know

1.5 Credits / Immunology, Allergy

November 21st 2024

Exploring Innovative Approaches in Myasthenia Gravis and the Specialty Pharmacist’s Role in Optimizing Value-Based Treatment

1.5 Credits / Immunology

November 21st 2024

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology

November 21st 2024

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology

November 21st 2024

Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape

1.0 Credit / Gastroenterology, Immunology, Rare Diseases

November 21st 2024

Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies

1.0 Credit / Immunology, Pulmonology/Respiratory

November 21st 2024

Managed Care Approaches to Individualize Treatment of Hereditary Angioedema

1.0 Credit / Immunology

November 21st 2024

From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care

1.5 Credits / Allergy, Immunology

More News

December 10th 2020

Dr David Pariser Highlights Comorbidities and Treatments in the Pipeline for Atopic Dermatitis

The comorbidities associated with atopic dermatitis can be substantial, and the disease can have a significant burden on quality of life, but new biologics and other future treatments may help, said David Pariser, MD, senior physician at Pariser Dermatology Specialists.

December 5th 2020

Dr David Pariser Discusses the Significant Burden of Atopic Dermatitis

The financial, physical, and social burdens of atopic dermatitis can be substantial, especially for patients who had the condition as children into adulthood, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.

December 4th 2020

National Asthma Guidelines Get First Update in 13 Years

Laura Joszt, MA

Updated guidance in 6 key areas of asthma care focus on improving diagnosis, management, and treatment.

November 28th 2020

Dr David Pariser Outlines Future Treatment Options of Atopic Dermatitis With Biologics and JAK Inhibitors

As the only biologic on the market, dupilumab has replaced most of the more traditional treatments for atopic dermatitis, said David Pariser, MD, senior physician at Pariser Dermatology Specialists.

November 25th 2020

Behavior Intervention Can Increase Physical Activity and Improve Asthma Control

Laura Joszt, MA

Patients with asthma can improve their disease control and sleep quality, while reducing depression and anxiety through a behavior change intervention aimed at increasing their physical activity.

November 17th 2020

Insurance Expansion Reduced Asthma Emergencies in New York City

Laura Joszt, MA

Expansion of insurance coverage due to the Affordable Care Act led to a reduction in the use of emergency services for patients with asthma in New York City.

November 15th 2020

Dupilumab Reduces Pain, Discomfort in Patients With Moderate to Severe Atopic Dermatitis

Laura Joszt, MA

Dupilumab, with or without topical corticosteroids, significantly reduced pain and discomfort in patients with moderate to severe atopic dermatitis.

Nicola Hanania, MD, MS, Baylor College of Medicine

November 11th 2020

Dr Nicola Hanania: Treatment of T2-High Asthma Is Constantly Evolving

Treatment targets include several interleukins, immunoglobulin E, and alarmins, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston.

November 8th 2020

Overuse of Reliever Inhalers Does Not Necessarily Mean Greater Health Care Utilization

Laura Joszt, MA

Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.

Anne Reihman, MD, University of Colorado

November 7th 2020

Dr Anne Reihman: Anti–IL-5 Therapies Can Be Life-Changing for Patients With Eosinophilic Asthma

Categorizing by eosinophilic/noneosinophilic subtype enables better targeted treatment, noted Anne Reihman, MD, third-year pulmonary and critical care fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine.

November 6th 2020

Vitamin D May Ease Symptoms of Severe Atopic Dermatitis in Children

Laura Joszt, MA

Vitamin D used as an adjuvant therapy in children with severe atopic dermatitis may improve clinical outcomes, according to a recent study.

October 31st 2020

Dr J. Allen Meadows Discusses Adherence to Biologics for Asthma

Despite the price, adherence to biologics for asthma is usually good because of the effectiveness, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

October 28th 2020

Weighing the Pros, Cons of At-Home Use of Biologics for Asthma

Laura Joszt, MA

When the first biologic to treat asthma was approved by the FDA in 2003, it needed to be administered subcutaneously in the physician’s office. Now, there are 3 options available for at-home use: mepolizumab, benralizumab, and dupilumab.

J. Allen Meadows, MD, president, American College of Allergy, Asthma & Immunology

October 22nd 2020

Dr J. Allen Meadows on Using Shared Decision-Making to Choose Among Biologics for Asthma

There are clear differences between the biologics approved to treat asthma, and finding the right one for a patient requires shared decision-making conversations, said J. Allen Meadows, MD.

October 19th 2020

Addressing the QOL Impact and Disease Burden on the Families of Adolescents With Atopic Dermatitis

Laura Joszt, MA

Atopic dermatitis (AD) has a negative impact on quality of life, and the burden of this disease in adolescents and their parents should be taken into account as part of the management of AD.

J. Allen Meadows, MD, American College of Allergy, Asthma & Immunology

October 14th 2020

Dr J. Allen Meadows on Making the Decision to Put a Patient With Asthma on a Biologic

Patients with severe asthma are good candidates for biologics, but choosing which biologic requires a shared decision-making conversation, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

October 14th 2020

Phase 3 Trial Finds Dupilumab Significantly Reduced Severe Asthma Attacks in Children

Laura Joszt, MA

Improvements in lung function occurred as early as 2 weeks after the first dose of treatment.

J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology

October 10th 2020

Dr J. Allen Meadows Outlines New Long-term Safety, Efficacy Data for Dupilumab in Asthma

New data on the long-term efficacy and safety of dupilumab are very reassuring to patients with asthma, explained J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.

October 9th 2020

Dupilumab Improves Lung Function, Reduces Asthma Flares in Patients on High-Dose ICS

Laura Joszt, MA

Patients with type 2-high asthma who were being treated with high-dose inhaled corticosteroids (ICS) had reduced exacerbations and improved lung function when they were switched to dupilumab.

September 30th 2020

Dr Neal Jain Discusses Type 2 Inflammation in Asthma

The majority of patients with asthma have type 2 inflammation, and the introduction of dupilumab has changed the treatment space for these patients, said Neal Jain, MD, FAAP, FAAAAI.

September 26th 2020

Dr Neal Jain on the Real-World Results of Dupilumab in Asthma

In the real world, dupilumab has been as effective as the results in clinical trials, and patients are seeing low exacerbation rates, emergency department visits, and hospitalizations, explained Neal Jain, MD, FAAP, FAAAAI.

September 25th 2020

Pediatric Asthma Health Care Utilization Following Onset of COVID-19 Pandemic

Laura Joszt, MA

Following the onset of the coronavirus disease 2019 (COVID-19) pandemic, changes in pediatric asthma health care delivery patterns resulted in reduced hospital admissions and systemic steroid prescriptions in Philadelphia.

September 22nd 2020

Anthem, Apple to Study How to Improve Asthma Self-management With Everyday Devices

AJMC Staff

The 2-year study will investigate how devices like the Apple Watch and the iPhone can help patients with asthma better manage their condition.

September 19th 2020

Dr Neal Jain Discusses the Use of Dupilumab in Oral Steroid–Dependent Asthma

Patients who have oral corticosteroid–dependent asthma are recommended to use dupilumab, which reduces the use of oral steroids, explained Neal Jain, MD, FAAP, FAAAAI, of Arizona Allergy & Immunology Research.

September 17th 2020

Real-World Study Finds High Persistence With Dupilumab in Atopic Dermatitis

Laura Joszt, MA

The high rate of persistence found in the real-world study indicates dupilumab was well tolerated and patients were satisfied with its effectiveness.

September 12th 2020

Real-World Study: Dupilumab for Atopic Dermatitis More Effective Than Clinical Trial Results

Laura Joszt, MA

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.

September 11th 2020

Dr Neal Jain Explains How Dupilumab Differentiated Itself as a Late Entrant to the Asthma Market

Even though dupilumab was a late entrant to the market to treat asthma, its efficacy “speaks for itself,” said Neal Jain MD, FAAP, FAAAAI, of Arizona Allergy & Immunology Research, Arcadia Allergy & Asthma, and San Tan Allergy & Asthma.

September 4th 2020

Vitamin D No Better Than Placebo at Preventing Severe Asthma Attacks

Laura Joszt, MA

Findings from a new study in JAMA do not support the use of vitamin D3 supplementation to prevent severe asthma exacerbations in children with persistent asthma.

June 23rd 2020

AI Smartphone App Could Improve Diagnosis of Psoriasis, Atopic Dermatitis, Eczema

Laura Joszt, MA

Inflammatory skin diseases are often diagnosed by "first impression" and can be easily misdiagnosed. A new smartphone app using artificial intelligence (AI) may be able to assist with the diagnosis of psoriasis, atopic dermatitis, and eczema.

December 4th 2019

Study Examines Bereavement Stress as Factor in Psoriasis, Atopic Dermatitis

AJMC Staff

Acute stress was found to be a possible trigger following the loss of a partner, but not a factor in long-term risk for either disorder.

...

5 6 7 8 9 10 11 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions